UB Paderborn / Katalog / Suche / in CDI

102PHGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index

Annals of oncology, 2018-11, Vol.29 (suppl_9)

2018

Volltextzugriff (PDF)

115PHGCSG1301: A multicenter, double-blind, randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment

Annals of oncology, 2018-11, Vol.29 (suppl_9)

2018

Volltextzugriff (PDF)

1554TiPRANDOMIZED PHASE II TRIAL OF HANGE-SHASIN-TO VERSUS PLACEBO TO PREVENT DIARRHEA IN PATIENTS WITH METASTATIC COLORECTAL CANCER UNDER IRIS+BEV SECOND-LINE TREATMENT (HGCSG1301)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv541-iv541

2014

Volltextzugriff (PDF)

157P Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: updated analysis of anti-tumor efficacy

Annals of oncology, 2015-12, Vol.26, p.ix42-ix42

2015

Volltextzugriff (PDF)

158P A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer; The HGCSG1401 study -first report

Annals of oncology, 2015-12, Vol.26, p.ix42-ix42

2015

Volltextzugriff (PDF)

172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV

Annals of oncology, 2015-12, Vol.26, p.ix42-ix42

2015

Volltextzugriff (PDF)

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Annals of oncology, 2016-12, Vol.27, p.ix54-ix54

2016

Volltextzugriff (PDF)

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

190P Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the Glasgow Prognostic Score (GPS)

Annals of oncology, 2016-12, Vol.27, p.ix59-ix60

2016

Volltextzugriff (PDF)

190P Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the Glasgow Prognostic Score (GPS)

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?

Journal of thoracic oncology, 2022-02, Vol.17 (2), p.200-213

2022

Volltextzugriff (PDF)

2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV

European journal of cancer (1990), 2015-09, Vol.51, p.S358-S359

2015

Volltextzugriff (PDF)

2094 Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy

European journal of cancer (1990), 2015-09, Vol.51, p.S359-S359

2015

Volltextzugriff (PDF)

22 GHz continuum and spectral index maps of the galactic center region

Astronomy and astrophysics (Berlin), 1986, Vol.154 (1-2), p.176-180

1986

Volltextzugriff (PDF)

22-GHz continuum observations of the Carina nebula

Monthly notices of the Royal Astronomical Society, 1991-04, Vol.249 (4), p.716-721

1991

Volltextzugriff (PDF)

A 2v-supply Voltage 16Mb Sram Cell With Load-lock-CVD Poly And DCS-WSix Technologies

Symposium 1993 on VLSI Technology, 1993, p.67-68

1993

Volltextzugriff (PDF)

3D visualization of liver and its vascular structures and surgical planning system - Surgical simulation

2011 6th International Conference on Computer Sciences and Convergence Information Technology (ICCIT), 2011, p.939-944

2011

Volltextzugriff (PDF)

4-Phenyltetrahydroisoquinoline, but not nomifensine or cocaine, inhibits methamphetamine-induced dopamine release

European journal of pharmacology, 1993-08, Vol.240 (1), p.51-56

1993

Volltextzugriff (PDF)

430PThe prospective multicenter study of relation between 5-HIAA/substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapy (MEC)

Annals of oncology, 2018-11, Vol.29 (suppl_9)

2018

Volltextzugriff (PDF)

592P - Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/BEV) In Patients with Metastatic Colorectal Cancer -Updated Analysis-. Hokkaido Gastrointestinal Cancer Study Group (HGCSG) Trial

Annals of oncology, 2012-09, Vol.23, p.ix202-ix202

2012

Volltextzugriff (PDF)

636 ASSOCIATION BETWEEN AMINO ACIDS 70 AND 91 IN THE HCV CORE REGION AND SECOND-PHASE VIRAL DECLINE DURING ANTIVIRAL THERAPY FOR PATIENTS WITH HCV 1B

Journal of hepatology, 2009, Vol.50, p.S234-S234

2009

Volltextzugriff (PDF)

8-4 improvement of the Quality of Bahiagrass Using Somaclonal Variation : Evaluation of Regenerated Plants and the Progeny

Japanese Journal of Grassland Science, 2000/07/19, Vol.46(Separate), pp.276-277

2000

Volltextzugriff (PDF)

A 9.9 G-10.8 Gb/s rate-adaptive clock and data-recovery with no external reference clock for WDM optical fiber transmission

2002 IEEE International Solid-State Circuits Conference. Digest of Technical Papers (Cat. No.02CH37315), 2002, Vol.1, p.252-465 vol.1

2002

Volltextzugriff (PDF)

A 9.9G-10.8Gb/s rate-adaptive clock and data-recovery with no external reference clock for WDM optical fiber transmission

2002 IEEE International Solid-State Circuits Conference. Digest of Technical Papers (Cat. No.02CH37315), 2002, Vol.2, p.202-472

2002

Volltextzugriff (PDF)

9. The oncothermia method - Theory, practice and clinical evidences

Thermal Medicine, 2017-10, Vol.33 (3), p.92-93

2017

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

102PHGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index

115PHGCSG1301: A multicenter, double-blind, randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment

1554TiPRANDOMIZED PHASE II TRIAL OF HANGE-SHASIN-TO VERSUS PLACEBO TO PREVENT DIARRHEA IN PATIENTS WITH METASTATIC COLORECTAL CANCER UNDER IRIS+BEV SECOND-LINE TREATMENT (HGCSG1301)

157P Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: updated analysis of anti-tumor efficacy

158P A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer; The HGCSG1401 study -first report

172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

190P Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the Glasgow Prognostic Score (GPS)

190P Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the Glasgow Prognostic Score (GPS)

The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?

2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV

2094 Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy

22 GHz continuum and spectral index maps of the galactic center region

22-GHz continuum observations of the Carina nebula

A 2v-supply Voltage 16Mb Sram Cell With Load-lock-CVD Poly And DCS-WSix Technologies

3D visualization of liver and its vascular structures and surgical planning system - Surgical simulation

4-Phenyltetrahydroisoquinoline, but not nomifensine or cocaine, inhibits methamphetamine-induced dopamine release

430PThe prospective multicenter study of relation between 5-HIAA/substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapy (MEC)

592P - Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/BEV) In Patients with Metastatic Colorectal Cancer -Updated Analysis-. Hokkaido Gastrointestinal Cancer Study Group (HGCSG) Trial

636 ASSOCIATION BETWEEN AMINO ACIDS 70 AND 91 IN THE HCV CORE REGION AND SECOND-PHASE VIRAL DECLINE DURING ANTIVIRAL THERAPY FOR PATIENTS WITH HCV 1B

8-4 improvement of the Quality of Bahiagrass Using Somaclonal Variation : Evaluation of Regenerated Plants and the Progeny

A 9.9 G-10.8 Gb/s rate-adaptive clock and data-recovery with no external reference clock for WDM optical fiber transmission

A 9.9G-10.8Gb/s rate-adaptive clock and data-recovery with no external reference clock for WDM optical fiber transmission

9. The oncothermia method - Theory, practice and clinical evidences

Suchergebnisse filtern